Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 23 studies | 29% ± 13% | |
astrocyte | 19 studies | 48% ± 16% | |
oligodendrocyte precursor cell | 15 studies | 79% ± 22% | |
oligodendrocyte | 14 studies | 51% ± 16% | |
endothelial cell | 13 studies | 34% ± 15% | |
glutamatergic neuron | 11 studies | 71% ± 21% | |
GABAergic neuron | 10 studies | 60% ± 22% | |
neuron | 8 studies | 51% ± 19% | |
amacrine cell | 8 studies | 51% ± 20% | |
adipocyte | 8 studies | 30% ± 13% | |
retinal ganglion cell | 7 studies | 56% ± 20% | |
retina horizontal cell | 6 studies | 51% ± 13% | |
connective tissue cell | 5 studies | 27% ± 7% | |
retinal bipolar neuron | 5 studies | 52% ± 9% | |
interneuron | 5 studies | 64% ± 19% | |
OFF-bipolar cell | 5 studies | 46% ± 16% | |
ON-bipolar cell | 5 studies | 51% ± 20% | |
smooth muscle cell | 5 studies | 29% ± 16% | |
granule cell | 4 studies | 65% ± 16% | |
microglial cell | 4 studies | 36% ± 17% | |
glycinergic amacrine cell | 4 studies | 58% ± 21% | |
retinal pigment epithelial cell | 4 studies | 39% ± 18% | |
Mueller cell | 4 studies | 28% ± 14% | |
macrophage | 3 studies | 28% ± 12% | |
myofibroblast cell | 3 studies | 32% ± 1% | |
differentiation-committed oligodendrocyte precursor | 3 studies | 77% ± 11% | |
progenitor cell | 3 studies | 51% ± 15% | |
GABAergic amacrine cell | 3 studies | 59% ± 8% | |
rod bipolar cell | 3 studies | 42% ± 5% | |
abnormal cell | 3 studies | 22% ± 4% | |
adventitial cell | 3 studies | 22% ± 3% | |
ciliated cell | 3 studies | 20% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 5042.54 | 2642 / 2642 | 100% | 57.65 | 702 / 705 |
kidney | 79% | 607.49 | 70 / 89 | 74% | 3.76 | 667 / 901 |
breast | 99% | 4365.56 | 456 / 459 | 52% | 9.43 | 583 / 1118 |
ovary | 88% | 727.45 | 158 / 180 | 34% | 1.59 | 147 / 430 |
uterus | 99% | 1633.08 | 169 / 170 | 13% | 0.78 | 60 / 459 |
thymus | 70% | 523.94 | 457 / 653 | 39% | 2.99 | 236 / 605 |
prostate | 87% | 1080.89 | 214 / 245 | 22% | 0.66 | 108 / 502 |
bladder | 100% | 1223.57 | 21 / 21 | 7% | 0.36 | 33 / 504 |
adrenal gland | 22% | 150.15 | 57 / 258 | 81% | 8.36 | 186 / 230 |
adipose | 100% | 3853.15 | 1200 / 1204 | 0% | 0 | 0 / 0 |
intestine | 81% | 1548.00 | 781 / 966 | 4% | 0.19 | 19 / 527 |
blood vessel | 83% | 747.28 | 1114 / 1335 | 0% | 0 | 0 / 0 |
esophagus | 65% | 1141.86 | 945 / 1445 | 14% | 0.56 | 25 / 183 |
skin | 57% | 585.74 | 1039 / 1809 | 10% | 0.47 | 45 / 472 |
muscle | 50% | 438.17 | 401 / 803 | 0% | 0 | 0 / 0 |
stomach | 38% | 477.11 | 135 / 359 | 10% | 0.47 | 28 / 286 |
heart | 30% | 202.98 | 257 / 861 | 0% | 0 | 0 / 0 |
lung | 7% | 47.82 | 42 / 578 | 17% | 0.89 | 200 / 1155 |
pancreas | 1% | 4.58 | 2 / 328 | 18% | 0.98 | 32 / 178 |
tonsil | 0% | 0 | 0 / 0 | 13% | 0.45 | 6 / 45 |
liver | 0% | 0 | 0 / 226 | 11% | 0.44 | 46 / 406 |
spleen | 2% | 14.94 | 5 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.06 | 1 / 80 |
peripheral blood | 0% | 1.14 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0000398 | Biological process | mRNA splicing, via spliceosome |
GO_0120163 | Biological process | negative regulation of cold-induced thermogenesis |
GO_0008380 | Biological process | RNA splicing |
GO_0000381 | Biological process | regulation of alternative mRNA splicing, via spliceosome |
GO_0007399 | Biological process | nervous system development |
GO_0006396 | Biological process | RNA processing |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0005730 | Cellular component | nucleolus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_1990825 | Molecular function | sequence-specific mRNA binding |
GO_0003730 | Molecular function | mRNA 3'-UTR binding |
GO_0005515 | Molecular function | protein binding |
GO_0003729 | Molecular function | mRNA binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | NOVA1 |
Protein name | NOVA alternative splicing regulator 1 RNA-binding protein Nova-1 (Neuro-oncological ventral antigen 1) (Onconeural ventral antigen 1) (Paraneoplastic Ri antigen) (Ventral neuron-specific protein 1) |
Synonyms | |
Description | FUNCTION: Functions to regulate alternative splicing in neurons by binding pre-mRNA in a sequence-specific manner to activate exon inclusion or exclusion. It binds specifically to the sequences 5'-YCAY-3' and regulates splicing in only a subset of regulated exons . Binding to an exonic 5'-YCAY-3' cluster changes the protein complexes assembled on pre-mRNA, blocking U1 snRNP binding and exon inclusion, whereas binding to an intronic 5'-YCAY-3' cluster enhances spliceosome assembly and exon inclusion. Binding to 5'-YCAY-3' clusters results in a local and asymmetric action to regulate spliceosome assembly and alternative splicing in neurons. Binding to an exonic 5'-YCAY-3' cluster changed the protein complexes assembled on pre-mRNA, blocking U1 snRNP (small nuclear ribonucleoprotein) binding and exon inclusion, whereas binding to an intronic 5'-YCAY-3' cluster enhanced spliceosome assembly and exon inclusion. With NOVA1, they perform unique biological functions in different brain areas and cell types. Autoregulates its own expression by acting as a splicing repressor. Acts to activate the inclusion of exon E3A in the glycine receptor alpha-2 chain and of exon E9 in gamma-aminobutyric-acid receptor gamma-2 subunit via a distal downstream UCAU-rich intronic splicing enhancer. Acts to regulate a novel glycine receptor alpha-2 chain splice variant (alpha-2N) in developing spinal cord (By similarity). . |
Accessions | I3L2B5 ENST00000539517.7 [P51513-4] F8VW64 P51513 F8W659 ENST00000449198.6 F8VWX1 ENST00000547619.5 H0YHZ1 ENST00000546546.1 ENST00000574031.1 ENST00000347476.10 ENST00000483536.6 J3KQU3 ENST00000549146.5 ENST00000549571.5 F8VYI3 G8JLA5 ENST00000344429.9 [P51513-2] ENST00000465357.6 [P51513-5] |